| Business Summary | | ViroLogic,
Inc.,
a
biotechnology
company,
is
engaged
in
developing,
marketing
and
selling
products
to
guide
and
improve
treatment
of
viral
diseases.
The
Company
developed
PhenoSense,
a
proprietary
technology
designed
to
directly
measure
the
impact
of
genetic
mutations
on
drug
resistance
and
use
this
information
to
guide
therapy.
PhenoSense
has
been
utilized
in
testing
drug
resistance
in
viruses
that
cause
serious
viral
diseases,
such
as
AIDS,
hepatitis
B
and
hepatitis
C.
The
Company's
first
product,
PhenoSense
HIV,
is
a
test
that
directly
and
quantitatively
measures
resistance
of
a
patient's
HIV
to
anti-viral
drugs.
The
results
help
physicians
select
appropriate
drugs
for
their
HIV
patients.
ViroLogic
is
also
developing
PhenoSense
products
for
other
serious
viral
diseases,
and
is
collecting
PhenoSense
test
results
and
related
clinical
data
in
an
interactive
database,
which
the
Company
plans
to
make
available
to
physicians
for
use
in
therapy
guidance. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ViroLogic,
Inc.
is
a
biotechnology
company
developing
and
marketing
products
to
guide
and
improve
treatment
of
viral
diseases,
utilizing
a
method
of
directly
measuring
the
impact
of
genetic
mutations
on
drug
resistance.
For
the
six
months
ended
6/30/01,
revenue
totaled
$7.9
million,
up
from
$2.8
million.
Net
loss
applicable
to
Common
fell
51%
to
$12.9
million.
Results
reflect
growth
in
the
patient
testing
business,
partially
offset
by
higher
marketing
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| William Young, 56 Chairman,
Pres, CEO | $360K | -- | Karen Wilson, 37 CFO,
VP | -- | -- | Frank Barker, 58 VP,
Information Technology and CIO | 224K | -- | Robin Toft, 40 VP
of Sales and Marketing | 215K | $196K | Patricia Wray, 44 VP
of HR | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|